News | September 02, 2022
NATCO Pharma to sell stake in Nativita and assets of Pharma division
NATCO to sell 15% of shareholding in Nativita for euro 3,45,000 to Pharmasyntez-Nord
NATCO to sell 15% of shareholding in Nativita for euro 3,45,000 to Pharmasyntez-Nord
He has over 25+ years of experience in the pharmaceutical Industry and has been working with the company for the past 6 years
The company has reported total income of Rs. 918.9 crores during the period ended June 30, 2022.
This lawsuit has been filed in the Pennsylvania Federal Court. NATCO and its marketing partner Mylan
This agreement allows Natco to expand access to Covid-19 medicines in 105 countries in generic name
The cash consideration for the acquisition is US$ 18 million.
Natco Pharma has reported consolidated financial results for the period ended September 30, 2021
Nat-Lenalidomide, a generic alternative to Revlimid, expands affordable treatment options for patients with multiple myeloma and patients with transfusion-dependent anaemia due to myelodysplastic syndromes (MDS)
The company has strong product launches both in India and overseas
Arrow is the marketing partner in US
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)